The Transition from Atellica IM aTG Assay to Atellica IM aTgll

The Transition from Atellica IM aTG Assay to Atellica IM aTgII

Anti-thyroglobulin (aTG) measurements are used as an aid in the diagnosis of Hashimoto’s and Graves’ diseases, which are autoimmune diseases affecting the thyroid gland.

Join Dr. Josep M. Auge Fradera, an expert in thyroid disorders, as he reviews the role of anti-thyroglobulin antibodies and utilizes clinical case findings for examples of the value of testing. He will also present his analysis comparing the existing Atellica® anti-thyroglobulin (aTg) assay with the new Atellica anti-thyroglobulin (aTgII) assay and highlight the clinical benefits of aTgII.

Learning Objectives:

  • Recognize the role of anti-thyroglobulin antibodies in monitoring thyroid autoimmune disease and differentiated thyroid cancer patients
  • Understand why assay design influences the recovery of anti-thyroglobulin antibodies making clinical evaluation mandatory
  • Review a comparison of Atellica® IM aTg and Atellica IM aTgll performance through an independent study
  • Focus on clinical evaluation results when transitioning from Atellica IM aTg to Atellica IM aTgll


Josep M. Auge Fradera, MD, PhD
Biochemistry and Molecular Genetic Department
Hospital Clinic-Barcelona

Subscription Button Icon

Keep up to date on the latest trends in healthcare. Read about current developments, new products and upcoming events.